glp 1 drugs wikipedia Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Mapping the effectiveness and risks

Inhibition of SGLT-1 in the small intestine causes more glucose transport to the distal intestine and colon, resulting in greater fermentation of glucose to SCFAs by luminal bacteria and increased sustained release of GLP-1 in the distal intestine [174] (Fig

This changed when it launched Saxenda in the US last year and looks set to become the market leader among a handful of new treatments

References (this section): NEJM (2023): Phase 2 trial publication Eli Lilly: Phase 2 results (mentions 24.2% at 48 weeks as a secondary endpoint) Eli Lilly (Dec 2025): Phase 3 TRIUMPH-4 topline results announcement Retatrutide side effects: what trials report (not medical advice) Searches like retatrutide side effects and side effects of retatrutide usually refer to events reported in clinical trial publications and sponsor summaries

[DOI] [PubMed] [Google Scholar] 108.Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity

As a step therapy medication Contrave is a common step therapy requirement before insurance plans will approve GLP-1 medications like Wegovy or Zepbound

The Rise of GLP1 Drugs for Weight Loss GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a revolutionary class of injectable or oral medications originally developed for type 2 diabetes, but now widely used for chronic weight management